Preliminary Results from the IMMagine-1 Trial

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.

Ciera Freeman, MD, PhD, presents the results of the phase 2 iMMagine-1 trial, highlighting preliminary results of anitocabtagene autoleucel (anito-cel), an innovative BCMA-directed CAR T-cell therapy demonstrating deep and durable responses in relapsed/refractory multiple myeloma with a manageable safety profile.

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial